Protective role of ACE2 and its downregulation in SARS-CoV-2 infection leading to Macrophage Activation Syndrome: Therapeutic implications

Nehla Banu, Sandeep Surendra Panikar, Lizbeth Riera Leal, Annie Riera Leal, Nehla Banu, Sandeep Surendra Panikar, Lizbeth Riera Leal, Annie Riera Leal

Abstract

In light of the outbreak of the 2019 novel coronavirus disease (COVID-19), the international scientific community has joined forces to develop effective treatment strategies. The Angiotensin-Converting Enzyme (ACE) 2, is an essential receptor for cell fusion and engulfs the SARS coronavirus infections. ACE2 plays an important physiological role, practically in all the organs and systems. Also, ACE2 exerts protective functions in various models of pathologies with acute and chronic inflammation. While ACE2 downregulation by SARS-CoV-2 spike protein leads to an overactivation of Angiotensin (Ang) II/AT1R axis and the deleterious effects of Ang II may explain the multiorgan dysfunction seen in patients. Specifically, the role of Ang II leading to the appearance of Macrophage Activation Syndrome (MAS) and the cytokine storm in COVID-19 is discussed below. In this review, we summarized the latest research progress in the strategies of treatments that mainly focus on reducing the Ang II-induced deleterious effects rather than attenuating the virus replication.

Keywords: ACE2; COVID-19; Coronavirus; Macrophage Activation Syndrome (MAS); RAS system; SARS.

Conflict of interest statement

Declaration of competing interest The authors declare no competing financial interests.

Published by Elsevier Inc.

Figures

Graphical abstract
Graphical abstract
Fig. 1
Fig. 1
Illustration of ACE2 Downregulation in COVID-19 patient and appearance of MAS. The virus enters the host cell by interacting with the ACE2 receptor through its spike protein. Later, the virus downregulates the ACE2 expression that in turn upregulates Ang II. Ang II is a product of the RAS system obtained by the cleavage of Ang I by enzyme ACE. The upregulated Ang II interacts with its receptor AT1R and modulates the gene expression of several inflammatory cytokines via NF-κB signaling. This Ang II/AT1R interaction also influences the macrophage activation that in turn produces the inflammatory cytokines Thereby, inducing ARDS or MAS. Also, some metalloproteases like ADAM17 shed these proinflammatory cytokines and ACE2 receptors to the soluble form which aids in loss of the protective function of surface ACE2 and may increase SARS pathogenesis. The treatment with Glucocorticoids, AT1R inhibitor, and All-trans retinoic acid tends to inhibit NF-κB signaling thus reducing the cytokine storms thereby improving the severity of SARS-CoV2 infection.
Fig. 2
Fig. 2
Schematic representation of Angiotensin II effects. The interaction of Ang II with AT1R mediates the harmful effects leading to multi-organ failure.

References

    1. Cheng H. Organ-protective effect of angiotensin‐converting enzyme 2 and its effect on the prognosis of COVID-19. J. Med. Virol. 2020:1–5. doi: 10.1002/jmv.25785.
    1. Gheblawi MM. Angiotensin converting enzyme 2: SARS-CoV-2 receptor and regulator of the renin-angiotensin system. Circ. Res. 2020;126(10):1456–1474. doi: 10.1161/CIRCRESAHA.120.317015.
    1. Li W. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426(6965):450–454.
    1. Wan Y. Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus. J. Virol. 2020;94(7)
    1. South A.M. COVID-19, ACE2, and the cardiovascular consequences. Am. J. Physiol. Heart Circ. Physiol. 2020;318(5):H1084–H1090. doi: 10.1152/ajpheart.00217.2020.
    1. Glowacka I. Differential downregulation of ACE2 by the spike proteins of severe acute respiratory syndrome coronavirus and human coronavirus NL63. J. Virol. 2010;84(2):1198–1205.
    1. Kuba K. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat. Med. 2005;11(8):875–879.
    1. Kuba K. Trilogy of ACE2: a peptidase in the renin-angiotensin system, a SARS receptor, and a partner for amino acid transporters. Pharmacol. Ther. 2010;128(1):119–128.
    1. Xie X. Age- and gender-related difference of ACE2 expression in rat lung. Life Sci. 2006;78(19):2166–2171.
    1. Kittana N. Angiotensin-converting enzyme 2–Angiotensin 1-7/1-9 system: novel promising targets for heart failure treatment. Fundamental & Clinical Pharmacology. 2018;32(1):14–25.
    1. Donoghue M. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ. Res. 2000;87(5):E1–E9.
    1. Mehta P.K., Griendling K.K. Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am. J. Phys. Cell Phys. 2007;292(1):C82–C97.
    1. Greenberg B. An ACE in the hole alternative pathways of the renin angiotensin system and their potential role in cardiac remodeling. J. Am. Coll. Cardiol. 2008;52(9):755–757.
    1. Imanishi T. Addition of eplerenone to an angiotensin-converting enzyme inhibitor effectively improves nitric oxide bioavailability. Hypertension. 2008;51(3):734–741.
    1. Guang C. Three key proteases--angiotensin-I-converting enzyme (ACE), ACE2 and renin—within and beyond the renin-angiotensin system. Archives of Cardiovascular Diseases. 2012;105(6–7):373–385.
    1. Patel V.B. ACE2 Deficiency Worsens Epicardial Adipose Tissue Inflammation and Cardiac Dysfunction in Response to Diet-Induced Obesity. Diabetes. 2016;65(1):85–95. doi: 10.2337/db15-0399.
    1. He L. Expression of elevated levels of pro-inflammatory cytokines in SARS-CoV-infected ACE2+ cells in SARS patients: relation to the acute lung injury and pathogenesis of SARS. J. Pathol. 2006;210(3):288–297.
    1. McGonagle D. The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease. Autoimmun. Rev. 2020;19(6):102537. doi: 10.1016/j.autrev.2020.102537.
    1. Danilczyk U., Penninger J.M. Angiotensin-converting enzyme II in the heart and the kidney. Circ. Res. 2006;98(4):463–471.
    1. Kuba K. Multiple functions of angiotensin-converting enzyme 2 and its relevance in cardiovascular diseases. Circ. J. 2013;77(2):301–308.
    1. Hamming I. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J. Pathol. 2004;203(2):631–637.
    1. X L. Extravascular sources of lung angiotensin peptide synthesis in idiopathic pulmonary fibrosis. American Journal of Physiology. Lung Cellular and Molecular Physiology. 2006;(5):291.
    1. BD U. Angiotensin-TGF-beta 1 crosstalk in human idiopathic pulmonary fibrosis: autocrine mechanisms in myofibroblasts and macrophages. Curr. Pharm. Des. 2007;13(12)
    1. R W. Angiotensin II induces apoptosis in human and rat alveolar epithelial cells. Am. J. Phys. 1999;276(5)
    1. Uhal B.D. Angiotensin signalling in pulmonary fibrosis. Int. J. Biochem. Cell Biol. 2012;44(3):465–468.
    1. Jia H. Pulmonary angiotensin-converting enzyme 2 (ACE2) and inflammatory lung disease. Shock. 2016;46(3):239–248.
    1. Jia H.P. ACE2 receptor expression and severe acute respiratory syndrome coronavirus infection depend on differentiation of human airway epithelia. J. Virol. 2005;79(23):14614–14621.
    1. B M. MicroRNome analysis unravels the molecular basis of SARS infection in bronchoalveolar stem cells. PLoS One. 2009;(11):4.
    1. Imai Y. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature. 2005;436(7047):112–116.
    1. Gu H. Angiotensin-converting enzyme 2 inhibits lung injury induced by respiratory syncytial virus. Sci. Rep. 2016;6:19840.
    1. Zou Z. Angiotensin-converting enzyme 2 protects from lethal avian influenza A H5N1 infections. Nat. Commun. 2014;5:3594.
    1. GJ R.-P. Angiotensin converting enzyme 2 abrogates bleomycin-induced lung injury. J. Mol. Med. 2012;90(6) (Berlin, Germany)
    1. Jia H.P. Ectodomain shedding of angiotensin converting enzyme 2 in human airway epithelia. Am J Physiol Lung Cell Mol Physiol. 2009:L84–L96.
    1. DW L. Tumor necrosis factor-alpha convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2) J. Biol. Chem. 2005;(34):280.
    1. H S. Modulation of TNF-alpha-converting enzyme by the spike protein of SARS-CoV and ACE2 induces TNF-alpha production and facilitates viral entry. Proc. Natl. Acad. Sci. U. S. A. 2008;105(22)
    1. S H. TACE antagonists blocking ACE2 shedding caused by the spike protein of SARS-CoV are candidate antiviral compounds. Antivir. Res. 2010;85(3)
    1. S E. Detection of soluble angiotensin-converting enzyme 2 in heart failure: insights into the endogenous counter-regulatory pathway of the renin-angiotensin-aldosterone system. J. Am. Coll. Cardiol. 2008;(9):52.
    1. M S. Cell-specific functions of ADAM17 regulate the progression of thoracic aortic aneurysm. Circ. Res. 2018;(3):123.
    1. VB P. Angiotensin II induced proteolytic cleavage of myocardial ACE2 is mediated by TACE/ADAM-17: A positive feedback mechanism in the RAS. J. Mol. Cell. Cardiol. 2014:66.
    1. A K A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome. Critical Care (London, England) 2017;21(1)
    1. M H. Pharmacokinetics and pharmacodynamics of recombinant human angiotensin-converting enzyme 2 in healthy human subjects. Clin. Pharmacokinet. 2013;52(9)
    1. Gwathmey T.M. Angiotensin-(1-7)-ACE2 attenuates reactive oxygen species formation to angiotensin II within the cell nucleus. Hypertension. 2010;55(1):166.
    1. Gwathmey T.M. Review: novel roles of nuclear angiotensin receptors and signaling mechanisms. Am J Physiol Regul Integr Comp Physiol. 2012:R518–R530.
    1. Uhal B.D. 2011. Regulation of Alveolar Epithelial Cell Survival by the ACE-2/Angiotensin 1–7/Mas Axis.
    1. A M. Effect of an angiotensin II receptor blocker and two angiotensin converting enzyme inhibitors on transforming growth factor-beta (TGF-beta) and alpha-actomyosin (alpha SMA), important mediators of radiation-induced pneumopathy and lung fibrosis. Curr. Pharm. Des. 2007;13(13)
    1. A M.-K. Lisinopril ameliorates paraquat-induced lung fibrosis. Clinica Chimica Acta; International Journal of Clinical Chemistry. 2006:367(1–2.
    1. Y M. Perindopril and losartan attenuate bleomycin A5-induced pulmonary fibrosis in rats. Nan fang yi ke da xue xue bao = Journal of Southern Medical University. 2008;28(6)
    1. N C. Effect of losartan on lung fibrosis in neonatal rats with hyperoxia-induced chronic lung disease. Zhongguo dang dai er ke za zhi = Chinese Journal of Contemporary Pediatrics. 2007;9(6)
    1. Ling T.-Y. Identification of pulmonary Oct-4+ stem/progenitor cells and demonstration of their susceptibility to SARS coronavirus (SARS-CoV) infection in vitro. Proc. Natl. Acad. Sci. U. S. A. 2006;103(25):9530–9535.
    1. Chen Y. A novel subset of putative stem/progenitor CD34+Oct-4+ cells is the major target for SARS coronavirus in human lung. J. Exp. Med. 2007:2529–2536.
    1. V S. Diminazene attenuates pulmonary hypertension and improves angiogenic progenitor cell functions in experimental models. Am. J. Respir. Crit. Care Med. 2013;(6):187.
    1. F L. The functional study of human umbilical cord mesenchymal stem cells harbouring angiotensin-converting enzyme 2 in rat acute lung ischemia-reperfusion injury model. Cell Biochem. Funct. 2014;32(7)
    1. Harmer D. Quantitative mRNA expression profiling of ACE 2, a novel homologue of angiotensin converting enzyme. FEBS Lett. 2002;532(1):107–110.
    1. Paizis G. Chronic liver injury in rats and humans upregulates the novel enzyme angiotensin converting enzyme 2. Gut. 2005;54(12):1790–1796.
    1. Osterreicher C.H. Angiotensin-converting-enzyme 2 inhibits liver fibrosis in mice. Hepatology (Baltimore, Md.) 2009;50(3):929–938.
    1. Cao X. Angiotensin-converting enzyme 2/angiotensin-(1-7)/Mas axis activates Akt signaling to ameliorate hepatic steatosis. Sci. Rep. 2016;6:21592.
    1. Rajapaksha I.G. Liver-targeted angiotensin converting enzyme 2 therapy inhibits chronic biliary fibrosis in multiple drug-resistant gene 2-knockout mice. Hepatology Communications. 2019;3(12):1656–1673.
    1. Cao X. The ACE2/Ang-(1–7)/Mas axis can inhibit hepatic insulin resistance. Mol. Cell. Endocrinol. 2014;393(1):30–38.
    1. Mizuiri S. Expression of ACE and ACE2 in individuals with diabetic kidney disease and healthy controls. Am. J. Kidney Dis. 2008;51(4):613–623.
    1. Niimi R. Suppression of endotoxin-induced renal tumor necrosis factor-alpha and interleukin-6 mRNA by renin-angiotensin system inhibitors. Jpn. J. Pharmacol. 2002;88(2):139–145.
    1. Mezzano Sergio A. Angiotensin II and renal fibrosis. Hypertension. 2001;38(3):635–638.
    1. Lorenzo O. Angiotensin II increases parathyroid hormone-related protein (PTHrP) and the type 1 PTH/PTHrP receptor in the kidney. J. Am. Soc. Nephrol. 2002;13(6):1595.
    1. Ruiz-Ortega M. Angiotensin II regulates the synthesis of proinflammatory cytokines and chemokines in the kidney. Kidney Int. 2002;62:S12–S22.
    1. Liu Z. Loss of angiotensin-converting enzyme 2 enhances TGF-β/Smad-mediated renal fibrosis and NF-κB-driven renal inflammation in a mouse model of obstructive nephropathy. Lab. Investig. 2012;92(5):650–661.
    1. Iwai M., Horiuchi M. Devil and angel in the renin-angiotensin system: ACE-angiotensin II-AT1 receptor axis vs. ACE2-angiotensin-(1-7)-Mas receptor axis. Hypertens. Res. 2009;32(7):533–536.
    1. Gallagher P.E. Regulation of ACE2 in cardiac myocytes and fibroblasts. Am. J. Physiol. Heart Circ. Physiol. 2008;295(6):H2373–H2379.
    1. Goulter A.B. ACE2 gene expression is up-regulated in the human failing heart. BMC Med. 2004;2:19.
    1. Zisman L.S. Angiotensin-(1-7) formation in the intact human heart: in vivo dependence on angiotensin II as substrate. Circulation. 2003;108(14):1679–1681.
    1. Oudit G.Y. Angiotensin II-mediated oxidative stress and inflammation mediate the age-dependent cardiomyopathy in ACE2 null mice. Cardiovasc. Res. 2007;75(1):29–39.
    1. Gurley S.B. Altered blood pressure responses and normal cardiac phenotype in ACE2-null mice. J. Clin. Invest. 2006;116(8):2218–2225.
    1. Crackower M.A. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature. 2002;417(6891):822–828.
    1. Lovren F. Angiotensin converting enzyme-2 confers endothelial protection and attenuates atherosclerosis. Am. J. Physiol. Heart Circ. Physiol. 2008;295(4):H1377–H1384.
    1. Satou R. Inflammation as a regulator of the renin-angiotensin system and blood pressure. Curr. Hypertens. Rep. 2018;20(12):100.
    1. Huentelman M.J. Protection from angiotensin II-induced cardiac hypertrophy and fibrosis by systemic lentiviral delivery of ACE2 in rats. Exp. Physiol. 2005;90(5):783–790.
    1. Loot A.E. Angiotensin-(1-7) attenuates the development of heart failure after myocardial infarction in rats. Circulation. 2002;105(13):1548–1550.
    1. Xia H. Brain angiotensin-converting enzyme type 2 shedding contributes to the development of neurogenic hypertension. Circ. Res. 2013;113(9):1087–1096.
    1. Doobay M.F. Differential expression of neuronal ACE2 in transgenic mice with overexpression of the brain renin-angiotensin system. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology. 2007;292(1):R373–R381.
    1. Mecca A.P. Cerebroprotection by angiotensin-(1-7) in endothelin-1-induced ischaemic stroke. Exp. Physiol. 2011;96(10):1084–1096.
    1. Hammer A. Role of the receptor Mas in macrophage-mediated inflammation in vivo. Proc. Natl. Acad. Sci. 2016;113(49)
    1. Kovacs A. ACE2 drives dendritic cell function and neuroantigen specific immune responses. Brain Behav. Immun. 2013;29:S19.
    1. Feng Y. Brain-selective overexpression of human Angiotensin-converting enzyme type 2 attenuates neurogenic hypertension. Circ. Res. 2010;106(2):373–382.
    1. Sriramula S. Brain-targeted angiotensin-converting enzyme 2 overexpression attenuates neurogenic hypertension by inhibiting cyclooxygenase-mediated inflammation. Hypertension. 2015;65(3):577–586.
    1. Xia H. ACE2-mediated reduction of oxidative stress in the central nervous system is associated with improvement of autonomic function. PLoS One. 2011;6(7)
    1. Yamada K. Effect of a centrally active angiotensin-converting enzyme inhibitor, perindopril, on cognitive performance in a mouse model of Alzheimer's disease. Brain Res. 2010;1352:176–186.
    1. Hashimoto T. ACE2 links amino acid malnutrition to microbial ecology and intestinal inflammation. Nature. 2012;487(7408):477–481.
    1. Wang J. 2020. ACE2 Expression by Colonic Epithelial Cells Is Associated With Viral Infection, Immunity and Energy Metabolism.
    1. Cooper H.S. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab. Investig. 1993;69(2):238–249.
    1. Ghosh H.S. SIRT1 negatively regulates the mammalian target of rapamycin. PLoS One. 2010;5(2):e9199–e.
    1. Das U.N. Renin-angiotensin-aldosterone system in insulin resistance and metabolic syndrome. J Transl Int Med. 2016;4(2):66–72.
    1. Cabandugama P.K. The renin angiotensin aldosterone system in obesity and hypertension: roles in the cardiorenal metabolic syndrome. Med Clin North Am. 2017;101(1):129–137.
    1. Wong T.P. Upregulation of ACE2-ANG-(1–7)-Mas axis in jejunal enterocytes of type 1 diabetic rats: implications for glucose transport. American Journal of Physiology-Endocrinology and Metabolism. 2012;303(5):E669–E681.
    1. Shi T.T. Angiotensin-converting enzyme 2 regulates mitochondrial function in pancreatic β-cells. Biochem. Biophys. Res. Commun. 2018;495(1):860–866.
    1. Guleria R.S. Retinoic acid receptor-mediated signaling protects cardiomyocytes from hyperglycemia induced apoptosis: role of the renin-angiotensin system. J. Cell. Physiol. 2011;226(5):1292–1307.
    1. Collado A. Functional role of endothelial CXCL16/CXCR6-platelet-leucocyte axis in angiotensin II-associated metabolic disorders. Cardiovasc. Res. 2018;114(13):1764–1775.
    1. Kawai T. AT1 receptor signaling pathways in the cardiovascular system. Pharmacol. Res. 2017;125(Pt A):4–13.
    1. Nehme A. Atlas of tissue renin-angiotensin-aldosterone system in human: a transcriptomic meta-analysis. Sci. Rep. 2015;5
    1. Shi R.Z. Angiotensin II induces vascular endothelial growth factor synthesis in mesenchymal stem cells. Exp. Cell Res. 2009;315(1):10–15.
    1. Haznedaroglu I.C., Malkan U.Y. Local bone marrow renin-angiotensin system in the genesis of leukemia and other malignancies. Eur. Rev. Med. Pharmacol. Sci. 2016;20(19):4089–4111.
    1. Lin C. Angiotensin-converting enzyme is required for normal myelopoiesis. FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology. 2011;25(4):1145–1155.
    1. Azizi M. Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline. J. Clin. Invest. 1996;97(3):839–844.
    1. Genevay M.C. The synthetic tetrapeptide AcSDKP protects cells that reconstitute long-term bone marrow stromal cultures from the effects of mafosfamide (Asta Z 7654) Exp. Hematol. 1996;24(1):77–81.
    1. Haznedaroglu I.C. Thrombopoietin as a drug: biologic expectations, clinical realities, and future directions. Clin. Appl. Thromb. Hemost. 2002;8(3):193–212.
    1. Ishikawa M. Angiotensin II type 1 receptor signaling contributes to platelet-leukocyte-endothelial cell interactions in the cerebral microvasculature. Am. J. Physiol. Heart Circ. Physiol. 2007;292(5):H2306–H2315.
    1. Jeannin P. The roles of CSFs on the functional polarization of tumor-associated macrophages. FEBS J. 2018;285(4):680–699.
    1. Kim S. Angiotensin II regulation of proliferation, differentiation, and engraftment of hematopoietic stem cells. Hypertension. 2016;67(3):574–584.
    1. Thatcher S. Deficiency of ACE2 in bone-marrow-derived cells increases expression of TNF-α in adipose stromal cells and augments glucose intolerance in obese C57BL/6 mice. Int. J. Hypertens. 2012;2012
    1. Thatcher Sean E. Angiotensin-converting enzyme 2 deficiency in whole body or bone marrow–derived cells increases atherosclerosis in low-density lipoprotein receptor−/− mice. Arterioscler. Thromb. Vasc. Biol. 2011;31(4):758–765.
    1. Bracaglia C. Macrophage Activation Syndrome: different mechanisms leading to a one clinical syndrome. Pediatric Rheumatology Online Journal. 2017;15(1):5.
    1. Ravelli A. Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. J. Pediatr. 2005;146(5):598–604.
    1. Carter S.J. Macrophage activation syndrome in adults: recent advances in pathophysiology, diagnosis and treatment. Rheumatology. 2018;58(1):5–17.
    1. Ramos-Casals M. Adult haemophagocytic syndrome. Lancet. 2014;383(9927):1503–1516.
    1. Dunmire S.K. Primary EBV infection induces an expression profile distinct from other viruses but similar to hemophagocytic syndromes. PLoS One. 2014;9(1)
    1. Weiss E.S. Interleukin-18 diagnostically distinguishes and pathogenically promotes human and murine macrophage activation syndrome. Blood. 2018;131(13):1442–1455.
    1. Karakike E., Giamarellos-Bourboulis E.J. Macrophage activation-like syndrome: a distinct entity leading to early death in sepsis. Front. Immunol. 2019;10:55.
    1. P M. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet (London, England) 2020;395(10229)
    1. Poyiadji N. 2020. COVID-19–Associated Acute Hemorrhagic Necrotizing Encephalopathy: CT and MRI Features.
    1. Wu D., Yang X.O. TH17 responses in cytokine storm of COVID-19: an emerging target of JAK2 inhibitor Fedratinib. J. Microbiol. Immunol. Infect. 2020;53(3):368–370. doi: 10.1016/j.jmii.2020.03.005.
    1. Lerkvaleekul B., Vilaiyuk S. Macrophage activation syndrome: early diagnosis is key. Open access Rheumatology: Research and Reviews. 2018;10:117–128.
    1. Crayne C.B. The immunology of macrophage activation syndrome. Front. Immunol. 2019;10:119.
    1. Aulagnon F. Acute kidney injury in adults with hemophagocytic lymphohistiocytosis. Am. J. Kidney Dis. 2015;65(6):851–859.
    1. Kim M.M. Central nervous system (CNS) involvement is a critical prognostic factor for hemophagocytic lymphohistiocytosis. Korean J Hematol. 2012;47(4):273–280.
    1. Sakumura N. Soluble CD163, a unique biomarker to evaluate the disease activity, exhibits macrophage activation in systemic juvenile idiopathic arthritis. Cytokine. 2018;110:459–465.
    1. Zhang H. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. 2020;46(4):586–590.
    1. Leuschner F. Angiotensin-converting enzyme inhibition prevents the release of monocytes from their splenic reservoir in mice with myocardial infarction. Circ. Res. 2010;107(11):1364–1373.
    1. de Carvalho Santuchi M. Angiotensin-(1-7) and alamandine promote anti-inflammatory response in macrophages in vitro and in vivo. Mediat. Inflamm. 2019;2019
    1. Xie P. Modulation of angiotensin II-induced inflammatory cytokines by the Epac1-Rap1A-NHE3 pathway: implications in renal tubular pathobiology. Am J Physiol Renal Physiol. 2014:F1260–F1274.
    1. Agarwal D. Angiotensin II causes imbalance between pro- and anti-inflammatory cytokines by modulating GSK-3β in neuronal culture. Br. J. Pharmacol. 2013;169(4):860–874.
    1. A O. Upregulation of renin-angiotensin system during differentiation of monocytes to macrophages. J. Hypertens. 1999;17(4)
    1. Potter D.D. 1998. Evidence that Macrophages in Atherosclerotic Lesions Contain Angiotensin II.
    1. Swirski F.K. Identification of splenic reservoir monocytes and their deployment to inflammatory sites. Science. 2009;325(5940):612–616.
    1. K U. Angiotensin II induces migration and Pyk2/paxillin phosphorylation of human monocytes. Hypertension (Dallas, Tex.: 1979) 2001;37(2 Pt 2)
    1. Ziai F. Renal allograft protection with losartan in Fisher→Lewis rats: hemodynamics, macrophages, and cytokines. Kidney Int. 2000;57(6):2618–2625.
    1. J S. Mas receptor deficiency augments angiotensin II-induced atherosclerosis and aortic aneurysm ruptures in hypercholesterolemic male mice. J. Vasc. Surg. 2019;70(5)
    1. H C. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet (London, England) 2020;395(10223)
    1. G C. Clinical and immunological features of severe and moderate coronavirus disease 2019. J. Clin. Invest. 2020;130(5)
    1. Gong J. 2020. Correlation Analysis Between Disease Severity and Inflammation-related Parameters in Patients with COVID-19 Pneumonia.
    1. Q C. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin. Infect. Dis. 2020 doi: 10.1093/cid/ciaa248.
    1. Jurewicz M. Human T and natural killer cells possess a functional renin-angiotensin system: further mechanisms of angiotensin II–induced inflammation. J. Am. Soc. Nephrol. 2007;18(4):1093.
    1. Muller D.N. Immunosuppressive treatment protects against angiotensin II-induced renal damage. Am. J. Pathol. 2002;161(5):1679–1693.
    1. Rupérez M. Connective tissue growth factor is a mediator of angiotensin II-induced fibrosis. Circulation. 2003;108(12):1499–1505.
    1. Jia L. Angiotensin II induces inflammation leading to cardiac remodeling. Frontiers in Bioscience (Landmark Edition) 2012;17:221–231.
    1. Kratochvill F. TNF counterbalances the emergence of M2 tumor macrophages. Cell Rep. 2015;12(11):1902–1914.
    1. Arango Duque G., Descoteaux A. Macrophage cytokines: involvement in immunity and infectious diseases. Front. Immunol. 2014;5:491.
    1. A N. Effect of beta(2)-adrenoceptor activation and angiotensin II on tumour necrosis factor and interleukin 6 gene transcription in the rat renal resident macrophage cells. Cytokine. 1999;11(10)
    1. Ferreri N.R. Angiotensin II Induces TNF Production by the Thick Ascending Limb: Functional Implications. 1998.
    1. Abel S. The transmembrane CXC-chemokine ligand 16 is induced by IFN-gamma and TNF-alpha and shed by the activity of the disintegrin-like metalloproteinase ADAM10. J. Immunol. 2004;172(10):6362–6372.
    1. Veinotte L. CXCL16-positive dendritic cells enhance invariant natural killer T cell-dependent IFNγ production and tumor control. Oncoimmunology. 2016;5(6) doi: 10.1080/2162402X.2016.1160979.
    1. Keidar S. ACE2 activity is increased in monocyte-derived macrophages from prehypertensive subjects. Nephrol. Dial. Transplant. 2007;22(2):597–601.
    1. Dewald O. CCL2/Monocyte Chemoattractant Protein-1 regulates inflammatory responses critical to healing myocardial infarcts. Circ. Res. 2005;96(8):881–889.
    1. Mateo T. Angiotensin II-induced mononuclear leukocyte interactions with arteriolar and venular endothelium are mediated by the release of different CC chemokines. J. Immunol. 2006;176(9):5577.
    1. Zhou Z, et al. Heightened innate immune responses in the respiratory tract of COVID-19 patients. Cell Host Microbe.
    1. G W. Angiotensin II stimulates expression of the chemokine RANTES in rat glomerular endothelial cells. Role of the angiotensin type 2 receptor. J. Clin. Invest. 1997;100(5)
    1. M R.-O. Proinflammatory actions of angiotensins. Curr. Opin. Nephrol. Hypertens. 2001;10(3)
    1. Ito Y. Fractalkine expression and the recruitment of CX3CR1+ cells in the prolonged mesangial proliferative glomerulonephritis. Kidney Int. 2002;61(6):2044–2057.
    1. Guo R.-W. Angiotensin II induces NF-κB activation in HUVEC via the p38MAPK pathway. Peptides. 2006;27(12):3269–3275.
    1. MC T. Genetic Ace2 deficiency accentuates vascular inflammation and atherosclerosis in the ApoE knockout mouse. Circ. Res. 2010;107(7)
    1. H A. Angiotensin II AT1 receptor blockade decreases brain artery inflammation in a stress-prone rat strain. Ann. N. Y. Acad. Sci. 2004;1018
    1. A R. Effect of angiotensin II antagonism on the regression of kidney disease in the rat. Kidney Int. 2002;62(3)
    1. WB S. Angiotensin II AT1-receptor blockade inhibits monocyte activation and adherence in transgenic (mRen2)27 rats. J. Cardiovasc. Pharmacol. 1999;33(3)
    1. Menk M. Angiotensin II type 2 receptor agonist compound 21 attenuates pulmonary inflammation in a model of acute lung injury. J. Inflamm. Res. 2018;11:169–178.
    1. Rathinasabapathy A. vol. 9. 2018. The Selective Angiotensin II Type 2 Receptor Agonist, Compound 21, Attenuates the Progression of Lung Fibrosis and Pulmonary Hypertension in an Experimental Model of Bleomycin-Induced Lung Injury. (180)
    1. Yanagitani Y. 1999. Angiotensin II Type 1 Receptor–Mediated Peroxide Production in Human Macrophages.
    1. NE H. Regulation of T-cell function by endogenously produced angiotensin II. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology. 2009;296(2)
    1. Jackson S.H. T cells express a phagocyte-type NADPH oxidase that is activated after T cell receptor stimulation. Nat. Immunol. 2004;5(8):818–827.
    1. A C. Differential expression and regulation of ADAM17 and TIMP3 in acute inflamed intestinal epithelia. Am. J. Physiol. Gastrointest. Liver Physiol. 2009;296(6)
    1. J P. A disintegrin and metalloproteinase 17 (ADAM17) mediates inflammation-induced shedding of syndecan-1 and -4 by lung epithelial cells. J. Biol. Chem. 2010;285(1)
    1. D D. Lung endothelial ADAM17 regulates the acute inflammatory response to lipopolysaccharide. EMBO Molecular Medicine. 2012;4(5)
    1. A C. Critical role of the disintegrin metalloprotease ADAM17 for intestinal inflammation and regeneration in mice. J. Exp. Med. 2010;207(8)
    1. M C. The lack of ADAM17 activity during embryonic development causes hemorrhage and impairs vessel formation. PLoS One. 2010;5(10)
    1. J S. ADAM17: a molecular switch to control inflammation and tissue regeneration. Trends Immunol. 2011;32(8)
    1. Y L. ADAM17 deficiency by mature neutrophils has differential effects on L-selectin shedding. Blood. 2006;108(7)
    1. JH B. Role of ADAM17 in the ectodomain shedding of TNF-alpha and its receptors by neutrophils and macrophages. J. Leukoc. Biol. 2007;82(1)
    1. RR K. Regulated release and functional modulation of junctional adhesion molecule A by disintegrin metalloproteinases. Blood. 2009;113(19)
    1. N S. Requirements for leukocyte transmigration via the transmembrane chemokine CX3CL1. Cellular and Molecular Life Sciences: CMLS. 2010;67(24)
    1. Driscoll W.S. 2013. Macrophage ADAM17 Deficiency Augments CD36-Dependent Apoptotic Cell Uptake and the Linked Anti-Inflammatory Phenotype.
    1. J T. Neutrophil and macrophage cell surface colony-stimulating factor 1 shed by ADAM17 drives mouse macrophage proliferation in acute and chronic inflammation. Mol. Cell. Biol. 2018;38(17)
    1. NM N. Ron receptor tyrosine kinase negatively regulates TNFalpha production in alveolar macrophages by inhibiting NF-kappaB activity and Adam17 production. Shock (Augusta, Ga.) 2010;33(2)
    1. N O. ADAM-9, ADAM-15, and ADAM-17 are upregulated in macrophages in advanced human atherosclerotic plaques in aorta and carotid and femoral arteries—Tampere vascular study. Ann. Med. 2009;41(4)
    1. Ohtsu H. 2006. ADAM17 Mediates Epidermal Growth Factor Receptor Transactivation and Vascular Smooth Muscle Cell Hypertrophy Induced by Angiotensin II.
    1. SY Z. Upregulation of Nox4 promotes angiotensin II-induced epidermal growth factor receptor activation and subsequent cardiac hypertrophy by increasing ADAM17 expression. The Canadian Journal of Cardiology. 2013;29(10)
    1. Oikawa H. 2020. A Disintegrin and Metalloproteinase 17 (ADAM17) Mediates Epidermal Growth Factor Receptor Transactivation by Angiotensin II on Hepatic Stellate Cells. undefined.
    1. X M. Angiotensin-(1-7)/Mas signaling inhibits lipopolysaccharide-induced ADAM17 shedding activity and apoptosis in alveolar epithelial cells. Pharmacology. 2016;97(1–2)
    1. M S. Loss of smooth muscle cell disintegrin and metalloproteinase 17 transiently suppresses angiotensin II-induced hypertension and end-organ damage. J. Mol. Cell. Cardiol. 2017:103.
    1. Xu J. 2017. Clinical Relevance and Role of Neuronal AT1 Receptors in ADAM17-Mediated ACE2 Shedding in Neurogenic Hypertension.
    1. Y L. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci. China Life Sci. 2020;63(3)
    1. Liu Q. miRNA-200c-3p is crucial in acute respiratory distress syndrome. Cell Discovery. 2017;3
    1. Chamsi-Pasha M.A.R. Angiotensin-converting enzyme 2 as a therapeutic target for heart failure. Current Heart Failure Reports. 2014;11(1):58–63.
    1. Xianwei W. Cross-Talk Between Inflammation and Angiotensin II: Studies Based on Direct Transfection of Cardiomyocytes With AT1R and AT2R cDNA. 2012.
    1. ND V. Intra-renal angiotensin II/AT1 receptor, oxidative stress, inflammation, and progressive injury in renal mass reduction. J. Pharmacol. Exp. Ther. 2007;323(1)
    1. J R. Role of angiotensin II type 1 receptor on renal NAD(P)H oxidase, oxidative stress and inflammation in nitric oxide inhibition induced-hypertension. Life Sci. 2015:124.
    1. P M. Effect of asiatic acid on the Ang II-AT 1 R-NADPH oxidase-NF-κB pathway in renovascular hypertensive rats. Naunyn Schmiedeberg's Arch. Pharmacol. 2017;390(10)
    1. Nagai N. Suppression of ocular inflammation in endotoxin-induced uveitis by blocking the angiotensin II type 1 receptor. Invest. Ophthalmol. Vis. Sci. 2020;46(8):2925–2931.
    1. Liu T.J. AT1R blocker losartan attenuates intestinal epithelial cell apoptosis in a mouse model of Crohn's disease. Mol. Med. Rep. 2020;13(2):1156–1162.
    1. Y C. Inhibition of angiotension II type 1 receptor reduced human endothelial inflammation induced by low shear stress. Exp. Cell Res. 2017;360(2)
    1. Lanz T.V. 2010. Angiotensin II Sustains Brain Inflammation in Mice Via TGF-β.
    1. Kurihara T. Neuroprotective effects of angiotensin II type 1 receptor (AT1R) blocker, telmisartan, via modulating AT1R and AT2R signaling in retinal inflammation. Invest. Ophthalmol. Vis. Sci. 2020;47(12):5545–5552.
    1. Fukuzawa M. Angiotensin converting enzyme inhibitors suppress production of tumor necrosis factor-alpha in vitro and in vivo. Immunopharmacology. 1997;36(1):49–55.
    1. Stenvinkel P. Do ACE-inhibitors suppress tumour necrosis factor-α production in advanced chronic renal failure? J. Intern. Med. 1999;246(5):503–507.
    1. Weidanz J.O.N.A. AT1R blockade reduces IFN-γ production in lymphocytes in vivo and in vitro. Kidney Int. 2005;67(6):2134–2142.
    1. Müller D.N. Angiotensin II (AT(1)) receptor blockade reduces vascular tissue factor in angiotensin II-induced cardiac vasculopathy. Am. J. Pathol. 2000;157(1):111–122.
    1. RE S. Additional antiproteinuric effect of ultrahigh dose candesartan: a double-blind, randomized, prospective study. Journal of the American Society of Nephrology: JASN. 2005;16(10)
    1. SO T. Candesartan prevents long-term impairment of renal function in response to neonatal partial unilateral ureteral obstruction. American Journal of Physiology. Renal Physiology. 2007;292(2)
    1. W B. Candesartan and glycyrrhizin ameliorate ischemic brain damage through downregulation of the TLR signaling cascade. Eur. J. Pharmacol. 2014:724.
    1. PB S. Telmisartan attenuated LPS-induced Neuroinflammation in human IMR-32 neuronal cell line via SARM in AT1R independent mechanism. Life Sci. 2015:130.
    1. T P. Telmisartan directly ameliorates the neuronal inflammatory response to IL-1β partly through the JNK/c-Jun and NADPH oxidase pathways. J. Neuroinflammation. 2012;9
    1. T S. Candesartan reduces superoxide production after global cerebral ischemia. Neuroreport. 2005;16(4)
    1. T N. Role of renin-angiotensin system and nuclear factor-kappaB in the obstructed kidney of rats with unilateral ureteral obstruction. Jpn. J. Pharmacol. 2002;90(4)
    1. Chen S. Candesartan suppresses chronic renal inflammation by a novel antioxidant action independent of AT1R blockade. Kidney Int. 2008;74(9):1128–1138.
    1. T P. Telmisartan ameliorates lipopolysaccharide-induced innate immune response through peroxisome proliferator-activated receptor-γ activation in human monocytes. J. Hypertens. 2012;30(1)
    1. J A. Losartan inhibits LPS-induced inflammatory signaling through a PPARgamma-dependent mechanism in human THP-1 macrophages. Hypertension Research: Official Journal of the Japanese Society of Hypertension. 2010;33(8)
    1. P M. Blocking angiotensin-converting enzyme induces potent regulatory T cells and modulates TH1- and TH17-mediated autoimmunity. Proc. Natl. Acad. Sci. U. S. A. 2009;106(35)
    1. Gao X.M. Inhibition of the Renin-Angiotensin System Post Myocardial Infarction Prevents Inflammation-Associated Acute Cardiac Rupture. Cardiovasc. Drugs Ther. 2017;31(2):145–156. doi: 10.1007/s10557-017-6717-2.
    1. Sun M.L. Inhibitors of RAS might be a good choice for the therapy of COVID-19 pneumonia. Zhonghua Jie He He Hu Xi Za Zhi. 2020;43(0):E014.
    1. Kai H., Kai M. Interactions of coronaviruses with ACE2, angiotensin II, and RAS inhibitors—lessons from available evidence and insights into COVID-19. Hypertens. Res. 2020:1–7.
    1. Gurwitz D. Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. Drug Dev. Res. 2020 doi: 10.1002/ddr.21656.
    1. Ishiyama Y. Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. Hypertension. 2004;43(5):970–976.
    1. Ishiyama Y. 2004. Upregulation of Angiotensin-Converting Enzyme 2 After Myocardial Infarction by Blockade of Angiotensin II Receptors.
    1. Patel V.B. 2012. Cardioprotective Effects Mediated by Angiotensin II Type 1 Receptor Blockade and Enhancing Angiotensin 1–7 in Experimental Heart Failure in Angiotensin-Converting Enzyme 2–Null Mice.
    1. Upregulation of Angiotensin-Converting Enzyme (ACE) 2 in Hepatic Fibrosis by ACE Inhibitors - Huang - 2010 - Clinical and Experimental Pharmacology and Physiology. Wiley Online Library; 2020.
    1. S K. Mineralocorticoid receptor blocker increases angiotensin-converting enzyme 2 activity in congestive heart failure patients. Circ. Res. 2005;97(9)
    1. CS L. Regulation of angiotensin converting enzyme II by angiotensin peptides in human cardiofibroblasts. Peptides. 2010;31(7)
    1. Turner A.J., Hooper N.M. The angiotensin-converting enzyme gene family: genomics and pharmacology. Trends Pharmacol. Sci. 2002;23(4):177–183.
    1. Vaduganathan M. Renin–Angiotensin–Aldosterone System Inhibitors in Patients With Covid-19. 2020.
    1. J G. Coronavirus disease 2019 (COVID-19) and cardiovascular disease: a viewpoint on the potential influence of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers on onset and severity of severe acute respiratory syndrome coronavirus 2 infection. J. Am. Heart Assoc. 2020;9(7)
    1. Oudit G.Y., Penninger J.M. Recombinant human angiotensin-converting enzyme 2 as a new renin-angiotensin system peptidase for heart failure therapy. Current Heart Failure Reports. 2011;8(3):176–183.
    1. EH B. Murine recombinant angiotensin-converting enzyme 2 attenuates kidney injury in experimental Alport syndrome. Kidney Int. 2017;91(6)
    1. Treml B. Recombinant angiotensin-converting enzyme 2 improves pulmonary blood flow and oxygenation in lipopolysaccharide-induced lung injury in piglets. Crit. Care Med. 2010;38(2):596–601. doi: 10.1097/CCM.0b013e3181c03009.
    1. Oudit G.Y. Human recombinant ACE2 reduces the progression of diabetic nephropathy. Diabetes. 2010:529–538.
    1. A K. Recombinant angiotensin-converting enzyme 2 suppresses pulmonary vasoconstriction in acute hypoxia. Wilderness & Environmental Medicine. 2012;23(1)
    1. RL K. Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China. F1000Research. 2020:9.
    1. Lei C. 2020. Potent Neutralization of 2019 Novel Coronavirus by Recombinant ACE2-Ig.
    1. Zhong J. 2010. Angiotensin-Converting Enzyme 2 Suppresses Pathological Hypertrophy, Myocardial Fibrosis, and Cardiac Dysfunction.
    1. Z J. Prevention of angiotensin II-mediated renal oxidative stress, inflammation, and fibrosis by angiotensin-converting enzyme 2. Hypertension (Dallas, Tex.: 1979) 2011;57(2)
    1. JG C. Inhibition of tumor necrosis factor-alpha (TNF-alpha) production and arthritis in the rat by GW3333, a dual inhibitor of TNF-alpha-converting enzyme and matrix metalloproteinases. J. Pharmacol. Exp. Ther. 2001;298(3)
    1. Wong E. Harnessing the natural inhibitory domain to control TNFα converting enzyme (TACE) activity in vivo. Sci. Rep. 2016;6(1):1–12.
    1. Moss M.L. Drug insight: tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis. Nat. Clin. Pract. Rheumatol. 2008;4(6):300–309.
    1. ML M. Drug insight: tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis. Nat. Clin. Pract. Rheumatol. 2008;4(6)
    1. A J., E C. ADAM17 as a therapeutic target in multiple diseases. Curr. Pharm. Des. 2009;15(20)
    1. Moss M.L., Minond D. Recent advances in ADAM17 research: a promising target for cancer and inflammation. Mediat. Inflamm. 2017;2017
    1. S U. ADAM17 regulates IL-1 signaling by selectively releasing IL-1 receptor type 2 from the cell surface. Cytokine. 2015;71(2)
    1. Y O. TACE cleaves neogenin to desensitize cortical neurons to the repulsive guidance molecule. Neurosci. Res. 2011;71(1)
    1. Adrain C. Tumor necrosis factor signaling requires iRhom2 to promote trafficking and activation of TACE. Science. 2012;335(6065):225–228.
    1. McIlwain D.R. iRhom2 regulation of TACE controls TNF-mediated protection against Listeria and responses to LPS. Science. 2012;335(6065):229–232.
    1. R-J S. ADAM17, shedding, TACE as therapeutic targets. Pharmacol. Res. 2013:71.
    1. Muller D.N. NF-kappaB inhibition ameliorates angiotensin II-induced inflammatory damage in rats. Hypertension. 2000;35(1):193–201. Pt 2.
    1. Nissen R.M., Yamamoto K.R. The glucocorticoid receptor inhibits NFkappaB by interfering with serine-2 phosphorylation of the RNA polymerase II carboxy-terminal domain. Genes Dev. 2000;14(18):2314–2329.
    1. De Bosscher K. The interplay between the glucocorticoid receptor and nuclear factor-kappaB or activator protein-1: molecular mechanisms for gene repression. Endocr. Rev. 2003;24(4):488–522.
    1. Jin X. Advanced glycation end products enhance macrophages polarization into M1 phenotype through activating RAGE/NF-κB pathway. Biomed. Res. Int. 2015;2015:732450.
    1. Jang S.E. Lactobacillus brevis G-101 ameliorates colitis in mice by inhibiting NF-κB, MAPK and AKT pathways and by polarizing M1 macrophages to M2-like macrophages. J. Appl. Microbiol. 2013;115(3):888–896.
    1. Gossye V. Differential mechanism of NF-kappaB inhibition by two glucocorticoid receptor modulators in rheumatoid arthritis synovial fibroblasts. Arthritis Rheum. 2009;60(11):3241–3250.
    1. Barnes P.J. Anti-inflammatory actions of glucocorticoids: molecular mechanisms. Clin Sci (Lond) 1998;94(6):557–572.
    1. Vandevyver S. New insights into the anti-inflammatory mechanisms of glucocorticoids: an emerging role for glucocorticoid-receptor-mediated transactivation. Endocrinology. 2013;154(3):993–1007.
    1. Vandevyver S. Glucocorticoid receptor dimerization induces MKP1 to protect against TNF-induced inflammation. J. Clin. Invest. 2012;122(6):2130–2140.
    1. Walsh G.M. Corticosteroids, eosinophils and bronchial epithelial cells: new insights into the resolution of inflammation in asthma. J. Endocrinol. 2003;178(1):37–43.
    1. Zhang N. Glucocorticoids enhance or spare innate immunity: effects in airway epithelium are mediated by CCAAT/enhancer binding proteins. J. Immunol. 2007;179(1):578–589.
    1. Sen E.S. Macrophage activation syndrome. Indian J. Pediatr. 2016;83(3):248–253.
    1. Petta I. The interactome of the glucocorticoid receptor and its influence on the actions of glucocorticoids in combatting inflammatory and infectious diseases. Microbiol. Mol. Biol. Rev. 2016;80(2):495–522.
    1. Notter M.F.D., Docherty J.J. Steroid hormone alteration of herpes simplex virus type 1 replication. J. Med. Virol. 1978;2(3):247–252.
    1. Erlandsson A.C. Herpes simplex virus type 1 infection and glucocorticoid treatment regulate viral yield, glucocorticoid receptor and NF-kappaB levels. J. Endocrinol. 2002;175(1):165–176.
    1. Kino T. Glucocorticoids suppress human immunodeficiency virus type-1 long terminal repeat activity in a cell type-specific, glucocorticoid receptor-mediated fashion: direct protective effects at variance with clinical phenomenology. J. Steroid Biochem. Mol. Biol. 2000;75(4–5):283–290.
    1. Hanley T.M., Viglianti G.A. Nuclear receptor signaling inhibits HIV-1 replication in macrophages through multiple trans-repression mechanisms. J. Virol. 2011;85(20):10834–10850.
    1. Alvarez-Carbonell D. The glucocorticoid receptor is a critical regulator of HIV latency in human microglial cells. J. NeuroImmune Pharmacol. 2019;14(1):94–109.
    1. Markovitz B.P. Corticosteroids for the prevention and treatment of post-extubation stridor in neonates, children and adults. Cochrane Database Syst. Rev. 2008;2:Cd001000.
    1. McCaffrey J. Corticosteroids to prevent extubation failure: a systematic review and meta-analysis. Intensive Care Med. 2009;35(6):977–986.
    1. Liu Q. Mesenchymal stem cells modified with angiotensin-converting enzyme 2 are superior for amelioration of glomerular fibrosis in diabetic nephropathy. Diabetes Res. Clin. Pract. 2020;162
    1. Mei S.H.J. Prevention of LPS-induced acute lung injury in mice by mesenchymal stem cells overexpressing angiopoietin 1. PLoS Med. 2007;4(9):e269.
    1. He H. Mesenchymal stem cells overexpressing angiotensin-converting enzyme 2 rescue lipopolysaccharide-induced lung injury. Cell Transplant. 2015;24(9):1699–1715.
    1. Singh N. ACE2/Ang-(1-7)/Mas axis stimulates vascular repair-relevant functions of CD34+ cells. Am. J. Physiol. Heart Circ. Physiol. 2015;309(10):H1697–H1707.
    1. Ortiz L.A. Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects. Proc. Natl. Acad. Sci. U. S. A. 2003;100(14):8407–8411.
    1. Grove J.E. Marrow-derived cells as vehicles for delivery of gene therapy to pulmonary epithelium. Am. J. Respir. Cell Mol. Biol. 2002;27(6):645–651.
    1. Leng Z. Transplantation of ACE2(−) mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia. Aging Dis. 2020;11(2):216–228.
    1. Takeda K. Downregulation of angiotensin II type 1 receptor by all-trans retinoic acid in vascular smooth muscle cells. Hypertension. 2000;35(1):297–302. Pt 2.
    1. Pan J. Molecular mechanisms of retinoid receptors in diabetes-induced cardiac remodeling. J. Clin. Med. 2014;3(2):566–594.
    1. Datta P.K., Lianos E.A. Retinoic acids inhibit inducible nitric oxide synthase expression in mesangial cells. Kidney Int. 1999;56(2):486–493.
    1. Nizamutdinova I.T. Retinoic acid protects cardiomyocytes from high glucose-induced apoptosis through inhibition of NF-κB signaling pathway. J. Cell. Physiol. 2013;228(2):380–392.
    1. Zhong J.C. Upregulation of angiotensin-converting enzyme 2 by all-trans retinoic acid in spontaneously hypertensive rats. Hypertension. 2004;44(6):907–912.
    1. Jang Y. Cerebral autoinflammatory disease treated with anakinra. Annals of Clinical and Translational Neurology. 2018;5(11):1428–1433.
    1. Adam Monteagudo L. Continuous intravenous anakinra infusion to calm the Cytokine storm in macrophage activation syndrome. ACR Open Rheumatol. 2020;2(5):276–282. doi: 10.1002/acr2.11135.
    1. Sönmez H.E. Anakinra treatment in macrophage activation syndrome: a single center experience and systemic review of literature. Clin. Rheumatol. 2018;37(12):3329–3335.
    1. Shakoory B. Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome: reanalysis of a prior phase III trial. Crit. Care Med. 2016;44(2):275–281.
    1. Schulert G.S., Grom A.A. Pathogenesis of macrophage activation syndrome and potential for cytokine- directed therapies. Annu. Rev. Med. 2015;66:145–159.
    1. McCreary E., Pogue J. COVID-19 treatment: a review of early and emerging options. Open Forum Infectious Diseases. 2020:7.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren